menu
    • menu
    [{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2022","type":"Collaboration","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Lantheus Holding \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Perspective Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"212-Pb VMT-alpha-NET","moa":"PSMA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantheus Holding \/ Perspective Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Lantheus Holding \/ Perspective Therapeutics"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SSTR","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantheus Holding \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Inapplicable"},{"orgOrder":0,"company":"Lantheus Holding","sponsor":"Point Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu PNT2002","moa":"Beta radiation","graph1":"Oncology","graph2":"Phase III","graph3":"Lantheus Holding","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lantheus Holding \/ Point Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Lantheus Holding \/ Point Biopharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Lantheus Holding

    Menu

    Lantheus Holding

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Dotatate Lutenium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lantheus Announces Acceptance of ANDA for Generic LUTATHERA®

                            Details : Lutathera-Generic (Lutetium Lu 177 Dotatate) is a radiolabeled somatostatin analog for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

                            Product Name : Lutathera-Generic

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            November 01, 2024

                            Lead Product(s) : 177-Lu Dotatate Lutenium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 212-Pb VMT-alpha-NET

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Perspective Therapeutics

                            Deal Size : $61.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lantheus Expands Radiopharmaceutical Oncology Pipeline through Strategic Agreements

                            Details : Under the agreement, Lantheus obtains an exclusive license for Perspective’s Pb212-VMT-⍺-NET, a clinical-stage alpha therapy developed for the treatment of neuroendocrine tumors.

                            Product Name : 212-Pb VMT-alpha-NET

                            Product Type : Other Small Molecule

                            Upfront Cash : $28.0 million

                            September 01, 2024

                            Lead Product(s) : 212-Pb VMT-alpha-NET

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Perspective Therapeutics

                            Deal Size : $61.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu PNT2002

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castrat...

                            Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy under phase 3 clinical development for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.

                            Product Name : 177-Lu PNT2002

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Inapplicable

                            December 18, 2023

                            Lead Product(s) : 177-Lu PNT2002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Point Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Lantheus Holding

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lantheus Announces Collaboration to Support Prostate Cancer Clinical Development

                            Details : As part of the agreement with Novartis, Lantheus will provide PYLARIFY for the selection of patients with prostate cancer and Novartis will provide all PYLARIFY related clinical imaging data to Lantheus.

                            Product Name : Pluvicto

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            March 29, 2022

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth